Molecular Profile of Intrahepatic Cholangiocarcinoma

Andraus, Wellington; Tustumi, Francisco; de Meira Junior, José Donizeti; Pinheiro, Rafael Soares Nunes; Waisberg, Daniel Reis; Lopes, Liliana Ducatti; Arantes, Rubens Macedo; Rocha Santos, Vinicius; de Martino, Rodrigo Bronze; Carneiro D’Albuquerque, Luiz Augusto

doi:10.3390/ijms25010461

Cited by 1 publication

(1 citation statement)

References 90 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis is usually dismal, with a reported 5-year overall survival of 10% to 35%. However, the prognosis is strictly related to stage and molecular profiles ( 5 ). The recommended treatment for advanced stages is chemotherapy combined with immunotherapy, with a median overall survival of less than one year ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

The role of living donor liver transplantation in treating intrahepatic cholangiocarcinoma

Andraus,

Ochoa,

de Martino

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

IntroductionIntrahepatic cholangiocarcinoma (iCC) is the liver’s second most common neoplasm. Until now, surgery is the only curative option, but only 35% of the cases are considered resectable at the diagnosis, with a post-resection survival of around 30%. Advancements in surgical techniques and perioperative care related to liver transplantation (LT) have facilitated the expansion of indications for hepatic neoplasms.MethodThis study is a comprehensive review of the global experience in living donor LT (LDLT) for treating iCC and describes our first case of LDLT for an unresectable iCC.ResultsWhile exploring LT for intrahepatic cholangiocarcinoma dates to the 1990s, the initial outcomes were discouraging, marked by poor survival and high recurrence rates. Nevertheless, contemporary perspectives underscore a reinvigorated emphasis on extending the frontiers of LT indications within the context of the “oncologic era.” The insights gleaned from examining explants, wherein incidental iCC was categorized as hepatocellular carcinoma in the preoperative period, have demonstrated comparable survival rates to small hepatocellular carcinoma. These findings substantiate the potential viability of LT as a curative alternative for iCC. Another investigated scenario pertains to “unresectable tumors with favorable biological behavior,” LT presents a theoretical advantage by providing free margins without the concern of a small future liver remnant. The constraint of organ shortage persists, particularly in nations with low donation rates. LDLT emerges as a viable and secure alternative for treating iCC.ConclusionLDLT is an excellent option for augmenting the graft pool, particularly in carefully selected patients.

show abstract

Section: Introductionmentioning

confidence: 99%